What substances does this Instanosis test strip detect?

The Instanosis Nitazene Test Strip is a rapid lateral flow immunoassay designed for the high-sensitivity screening of emerging synthetic opioids within the nitazene class (such as isotonitazene and metonitazene) in unknown substances, liquids, or drug residues.

What is the package size and configuration for this product?

This product configuration contains a Box of 25 or 100 individually wrapped test strips, providing a highly portable and convenient solution ideally suited for field harm reduction deployments, mobile public health outreach, and forensic toxicology screening.

Is this Nitazene test strip cleared for medical or clinical diagnostic use?

No. This specific product is strictly designated for Forensic and Field Harm Reduction applications only. It is not cleared for in vitro diagnostic (IVD) use, emergency room clinical toxicology, or human patient monitoring.

Can health networks, forensic labs, and public agencies purchase this kit through contract distributors?

Yes. Procurement departments, harm reduction networks, and forensic laboratories can source these 25-strip kits via direct institutional purchase orders or through primary scientific contract distributors such as Avantor/VWR.

Nitazene test strip, for forensic and harm reduction applications

Order through Avantor/VWR: Box of 25

Product Overview

The Instanosis Nitazene Test Strip is a high-sensitivity, rapid lateral flow assay manufactured in the USA for forensic and harm reduction applications. Featuring an advanced analytical detection cut-off threshold of 50 ng/mL, this standalone immunoassay strip accurately identifies benzimidazole synthetic opioids (including metonitazene and isotonitazene etc.) within complex drug matrices. Engineered for maximum sample preservation, it requires only 1/10th of the volume demanded by standard market alternative test strips, delivering definitive qualitative visual results within 5 minutes to support public health surveillance networks and forensic laboratories.

Technical Specifications & Key Data

This standalone lateral flow immunoassay is calibrated to detect emerging high-potency synthetic opioids before they escalate into localized public health crises:

Target Analyte Group: Benzimidazole opioids (Nitazenes, including metonitazene, isotonitazene and related analogs).
Analytical Limit of Detection (LOD): 50 ng/mL (calibrated to ensure broad cross-reactivity across the expanding nitazene chemical family).
Micro-Volume Efficiency: Requires 90% less sample amount (1/10th of competitive baseline requirements), ensuring critical primary compounds are preserved for confirmatory laboratory testing (GC-MS/LC-MS).
Assay Performance Window: Clear visual interpretation within 5 minutes.
Origin & Quality Standards: Developed under rigorous quality management frameworks under FDA QMSR and proudly Made in the U.S.

Public Health & Toxicological Significance

Nitazenes are structural variants of benzimidazole opioids originally developed by the pharmaceutical industry in the 1950s but never approved for human medical use due to severe respiratory depression risks.

Extreme Potency Profile: Certain nitazene analogs exhibit an overall clinical potency estimated to be up to 10 times greater than fentanyl and up to 1,000 times greater than morphine.
Supply Chain Adulteration: Nitazenes are increasingly deployed by illicit manufacturers to fortify low-potency heroin or counterfeit prescription opioids, frequently presenting as a hidden polysubstance component.
Severe Naloxone Requirements: Due to their exceptionally high affinity for mu-opioid receptors, nitazene-induced overdoses frequently manifest with rapid-onset respiratory arrest. High-sensitivity field test strips are essential early-warning tools for harm reduction deployment.

Frequently Asked Questions (FAQ)

Q1: What specific compounds can the Instanosis Nitazene test strip detect?

A: This immunoassay is explicitly optimized to recognize the benzimidazole opioid family, providing broad, high-affinity cross-reactivity for prominent synthetic analogs including metonitazene, isotonitazene and related drugs.

Q2: What is the exact analytical cut-off concentration for this strip?

A: The precise technical limit of detection (LOD) is calibrated at 50 ng/mL. This ultra-low threshold allows for successful identification of trace nitazene compounds even within highly diluted field samples.

Q3: How much sample material is required to execute a test?

A: Thanks to advanced antibody design and development, this product requires 1/10th of the sample amount typically demanded by standard competitor test strips, preserving the vast majority of your forensic or research sample.

Q4: Are nitazenes detectable by standard fentanyl test strips?

A: No. Nitazenes are chemically distinct benzimidazole compounds and completely lack the molecular structure of fentanyl. Standard fentanyl test strips will fail to detect them, making this standalone nitazene strip an essential addition to comprehensive polysubstance drug-checking protocols.

Q5: Is this product manufactured in the United States?

A: Yes. The Instanosis Nitazene test strip is entirely developed and manufactured in the USA in an FDA registered manufacturing facility compliant with QMSR quality standards.

Q6: Can these test strips be purchased through corporate laboratory distributors?

A: Yes. In addition to direct corporate accounts, public health agencies and academic labs can procure the Instanosis Box of 25 strips using our verified distribution listings on major scientific networks such as Avantor/VWR.